{"id":"second-line-antidepressants","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5858588","moleculeType":null,"molecularWeight":"430.62"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Second-line antidepressants encompass multiple drug classes (SNRIs, tricyclic antidepressants, atypical antidepressants, and others) that modulate different neurotransmitter systems beyond selective serotonin reuptake inhibition. These agents are typically used when SSRIs fail due to inadequate efficacy or intolerable side effects, offering alternative mechanisms such as dual serotonin-norepinephrine reuptake inhibition or alpha-2 antagonism to restore mood regulation.","oneSentence":"Second-line antidepressants work through various mechanisms including serotonin-norepinephrine reuptake inhibition, noradrenergic activity, or other neurotransmitter modulation to treat depression when first-line agents are ineffective or poorly tolerated.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:47.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder (treatment-resistant or SSRI-intolerant)"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Chronic pain syndromes"}]},"trialDetails":[{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT05973851","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2024-08-31","conditions":"Major Depressive Disorder, Treatment Resistant Depression","enrollment":418},{"nctId":"NCT02752542","phase":"PHASE4","title":"Personalized Indications for CBT and Antidepressants in Treating Depression","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2016-10-31","conditions":"Major Depressive Disorder, Persistent Depressive Disorder","enrollment":80},{"nctId":"NCT02564172","phase":"NA","title":"Conus Medullaris Stimulation With 5 Columns Lead Versus Medical Treatment in Refractory Pudendal Neuralgia","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2015-09-30","conditions":"Pudendal Neuralgia","enrollment":42},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT04996433","phase":"NA","title":"A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients","status":"RECRUITING","sponsor":"University of Greifswald","startDate":"2021-12-01","conditions":"Persistent Depressive Disorder, Treatment-resistant Depression","enrollment":396},{"nctId":"NCT05280015","phase":"PHASE2","title":"Microbiotherapy in Characterized Depressive Disorder","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-06-08","conditions":"Depression, Depressive Disorder, Depressive Disorder, Major","enrollment":92},{"nctId":"NCT03502187","phase":"NA","title":"Subacute Low Back Pain in Active Duty","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2018-04-17","conditions":"Subacute Low Back Pain","enrollment":133},{"nctId":"NCT03841682","phase":"NA","title":"Engaging Self-regulation Targets to Improve Mood and Weight and Understand Mechanism in Depressed and Obese Adults","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2019-03-01","conditions":"Obesity, Depression","enrollment":106},{"nctId":"NCT02696824","phase":"NA","title":"Effectiveness of Nurse-delivered Care for Adherence/Mood in HIV in South Africa","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-07-19","conditions":"Immunodeficiency Virus, Human, Depressive Symptoms","enrollment":161},{"nctId":"NCT03220308","phase":"NA","title":"Mindfulness Training for Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Mindful Parenting","status":"COMPLETED","sponsor":"Karakter Kinder- en Jeugdpsychiatrie","startDate":"2016-02-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":103},{"nctId":"NCT03500029","phase":"PHASE1","title":"The Study About Mechanism of Transcranial Magnetic Stimulation Treatment of Depression Using Medical Imaging","status":"UNKNOWN","sponsor":"Xi'an Jiaotong University","startDate":"2018-03-01","conditions":"Depression","enrollment":240},{"nctId":"NCT02593643","phase":"EARLY_PHASE1","title":"Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2016-01","conditions":"Major Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Second-line Antidepressants","genericName":"Second-line Antidepressants","companyName":"Dr. Inge Winter","companyId":"dr-inge-winter","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Second-line antidepressants work through various mechanisms including serotonin-norepinephrine reuptake inhibition, noradrenergic activity, or other neurotransmitter modulation to treat depression when first-line agents are ineffective or poorly tolerated. Used for Major depressive disorder (treatment-resistant or SSRI-intolerant), Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}